Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:N Engl J Med
Glavni autori: Connolly, Stuart J., Crowther, Mark, Eikelboom, John W., Gibson, C. Michael, Curnutte, John T., Lawrence, John H., Yue, Patrick, Bronson, Michele D., Lu, Genmin, Conley, Pamela B., Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T., Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M., Pallin, Daniel J., Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M., Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/
https://ncbi.nlm.nih.gov/pubmed/30730782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items